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Abstract. Numerous health benefits have been attributed to cocoa 
and its derived products in the last decade including antioxidant, 
anti-platelet and positive effects on lipid metabolism and vascular 
function. Inflammation plays a key role in the initiation and 
progression of atherosclerosis. However, cocoa feeding trials 
focused on inflammation are still rare and the results yielded are 
controversial. Health effects derived from cocoa consumption have  
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been partly attributed to its polyphenol content, in particular of flavanols. 
Bioavailability is a key issue for cocoa polyphenols in order to be able to exert their 
biological activities. In the case of flavanols, bioavailability is strongly influenced by 
several factors, such as their degree of polymerization and the food matrix in which the 
polyphenols are delivered. Furthermore, gut has become an active site for the 
metabolism of procyanidins (oligomeric and polymeric flavanols). Estimation of 
polyphenol consumption or exposure is also a very challenging task in Food and 
Nutrition Science in order to correlate the intake of phytochemicals with in vivo health 
effects. In the area of nutrition, modern analytical techniques based on mass 
spectrometry are leading to considerable advances in targeted metabolite analysis and 
particularly in Metabolomics or global metabolite analysis. 
      In this chapter we have summarized the most relevant results of our recent research 
on the bioavailability of cocoa polyphenols in humans and the effect of the matrix in 
which cocoa polyphenols are delivered considering both targeted analysis and a 
metabolomic approach. Furthermore, we have also summarized the effect of long-term 
consumption of cocoa powder in patients at high risk of cardiovascular disease (CVD) 
on the inflammatory biomarkers of atherosclerosis. 
 
Introduction 
 
 Cocoa (Theobroma cacao L.) and its related products are rich sources of 
antioxidant flavonoids, containing higher amounts per serving than other 
polyphenol rich foods such as red wine or tea [1]. Flavanols are the most 
abundant flavonoids in cocoa and comprise monomeric flavanols                     
[(+)-catechin and (-)-epicatechin], oligomeric (procyanidins B1, B2 and C1) 
and polymeric forms (procyanidins) [2].  
 Inflammation is central to cardiovascular disease. The process of 
atherosclerosis starts with inflammatory changes in the arterial endothelium, 
which in turn expresses a series of adhesion molecules that attract circulating 
monocytes, which migrate through the endothelial layer under the influence of 
various proinflammatory chemoattractants. Once within the arterial intima, the 
monocytes continue to undergo inflammatory changes, and through these 
inflammatory processes, the initial lesion of atherosclerosis, the fatty streak, is 
formed.  Also, inflammation is central to the progression from fatty streak to 
complex plaque that can lead to fatal complications [3]. 
 Evidence based on epidemiological studies supports the belief that regular 
consumption of cocoa-containing products may confer cardiovascular 
protection, reducing blood pressure and the risk of CVD mortality [4, 5]. In 
addition, a recent meta-analysis on the effectiveness of cocoa human feeding 
trials has suggested that cocoa and its derived products have a significant 
effect on endothelial function, increasing flow-mediated dilation and reducing 
systolic and diastolic blood pressures [6]. Other benefits from cocoa 
consumption are associated with their capacity to improve lipid levels and 
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insulin sensitivity, and to reduce platelet activation and function [7]. In 
addition, results from in vitro studies have shown that cocoa flavanols and 
procyanidins also present anti-inflammatory effects, suppressing the 
production of the proinflammatory molecules such as cytokines and 
chemokines [8, 9], which are produced in the initial phases of atherosclerosis. 
However, few human feeding trials have focused on the study of the anti-
inflammatory effects of cocoa, and the results obtained have been 
contradictory, reporting either neutral effects or changes in a single 
inflammatory biomarker [10-12]. 
 For these biological activities to be translated into real health effects          
in vivo, cocoa polyphenols need to be bioavailable. Bioavailability of flavanols 
is influenced by their degree of polymerization and the food matrix. While 
monomers are readily absorbed in the small intestine, oligomers and polymers 
need to be biotransformed by the colonic microbiota before absorption            
(Fig. 1). Equally important is the development of biomarkers of exposure in  
 
 
 
Figure 1. Scheme of bioavailability of cocoa flavanols showing phase II metabolites 
[conjugation by enzymes catechol-O-methyl transferases (COMT); uridine diphosphate 
glucuronyltransferases (UDPGT), and sulfotransferases (SULFT)], and microbial 
metabolites [degradation of oligomers and polymers by intestinal microbiota]. 
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order to correlate the intake of flavanols with particular health effects in vivo. 
In this sense, global analysis of metabolites or metabolomics is becoming an 
important tool for the determination of new biomarkers of exposure to 
polyphenols. 
 The other important aspect that could modulate the bioavailability of 
polyphenols is the food matrix. Several studies have provided conflicting 
evidence about the effect of milk on the bioavailability of polyphenols, 
specifically flavanols, when looking at their phase II conjugate forms from 
cocoa [13-16]. Recently, it has been suggested that the possible influence of 
milk on cocoa flavonoid absorption, and consequently on the urinary 
excretion of phase II metabolites, is more relevant for drinks with lower 
flavanol content, which is typical of many commercial cocoas, than for drinks 
with higher content [17]. Therefore, as milk significantly lowered the 
excretion of urinary phase II metabolites of cocoa flavanols [17], there is a 
need to study the effect of milk on the colonic microbial metabolism of the 
non-absorbed cocoa flavanol fraction that reaches the colon [18]. 
 Herein we will summarize the main results of our recent research on the 
bioavailability of cocoa polyphenols in two interventional studies: 1) A single 
dose study of cocoa powder whose main aims are: a) Effect of milk on the 
bioavailability of cocoa polyphenols [18], b) Metabolomic study to assess 
bioavailability and identify nutritional biomarkers of exposure after cocoa 
intake in humans [19]; 2) a long-term study of regular consumption of cocoa 
powder in patients at high risk of CVD whose main aims are: c) Effects of 
cocoa powder at clinical levels [20], and d) Targeted study of cocoa 
polyphenol metabolites to assess bioavailability and compliance [21]. 
 
1. Single cocoa powder intake: Short-term study 
 
1.1. Effect of milk on the bioavailability of cocoa polyphenols 
 
 The short term study with single intake of cocoa powder was a randomized, 
crossover and controlled clinical trial. Twenty-one healthy volunteers (9 women 
and 12 men) were included in the study. Participants were instructed to abstain 
from polyphenol-rich foods for at least 48 h before the study and during the day 
of the study. The study was done on three different days with one week between 
the interventions. After overnight fasting, the volunteers consumed three 
different meals in random order: a) 40 g cocoa powder (Nutrexpa, Barcelona, 
Spain) and 250 mL whole milk (CC-M); b) 40 g cocoa powder and 250 mL 
water (CC-W); c) 250 mL whole milk as a control [18]. 
 First, we evaluated the effect of milk on the absorption of (–)-epicatechin 
from cocoa powder. The only metabolite found in plasma at 2h after ingestion 
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of cocoa powder was epicatechin-glucuronide. The concentration of 
epicatechin glucuronide in plasma was ~20% higher after the intervention of 
CC-W in comparison to the intervention CC-M but these differences were 
almost significant (P=0.07) [14]. With respect to phase II metabolites of 
epicatechin in urine (three sulfates and one glucuronide conjugates), milk did 
not affect the total excretion of metabolites but affected the excretion profile 
of these conjugates [13]. 
 We have also evaluated the metabolism of cocoa polyphenols at a colonic 
microbial level (microbiota metabolites) through the measure of the urinary 
excretion of microbial-derived phenolic acids and evaluated the effect of milk 
on urinary excretion of these compounds after the intake of a standard portion 
of cocoa powder with either water or milk in an acute intervention using a 
targeted quantitative procedure. We have carried out this targeted study 
through a developed and validated methodology that consist in solid-phase 
extraction (SPE) of biological samples (urine) followed by LC-MS/MS 
analysis [22].  
 We evaluated the excretion of 15 phenolic acids which had been 
described as microbial degradation products of flavanols [21, 23-26]. Of the 
15 phenolic acids studied, the excretion of seven phenolic acids diminished 
after CC-M when compared with CC-W while two phenolic acids increased. 
Four phenolic acids of these seven, could come from the direct degradation of 
procyanidins by the intestinal microbiota following the scheme shown in Fig. 2. 
Procyanidins could be degraded forming 3,4-dihydroxyphenylacetic acid (Fig. 2) 
[18, 27] and this compound through α-oxidation could be degraded to 
protocatechuic acid [26]. Microbial dehydroxylation of protocatechuic acid 
could give rise to 4-hydroxybenzoic acid derivative that may undergo 
glycination in the liver and kidney being converted into 4-hydroxyhippuric 
acid [18, 24]. 
 Two hydroxycinnamic acids, caffeic and ferulic acids, were also 
significantly reduced (50% and 80%, respectively) by the ingestion of CC-M 
when compared with CC-W. In cocoa, these compounds could come from 
several routes of metabolism, which could include dehydrogenation of              
3,4-dihydroxyphenylpropionic acid as well as degradation from other phenolic 
derivatives present in cocoa powder, such as chlorogenic acid or               
N-phenylpropenoyl-L-amino acids [25, 28]. We observed a high concentration 
in the last urine fraction suggesting that a longer period of urine collection 
was required for their complete excretion. 
 Whereas a higher global urinary excretion of phenolic acids was observed 
with consumed CC-W, vanillic and phenylacetic acids showed an excretion 
pattern contrary to those of other metabolites. This result could mean that 
liposoluble vanillin, when ingested with CC-M, could be absorbed more easily  
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Figure 2. Urinary excretion [mean(SEM)] and percentage difference of four phenolic 
acids from cocoa procyanidins significantly affected by the consumption of cocoa 
powder with water or with milk [18]. Bars with an asterisk are significantly different 
(P < 0.05; Wilcoxon’s test; n = 21) in the same time period between water and milk. 
aDescribed in [27]. 
 
and rapidly than after its intake with CC-W and could be oxidized to vanillic 
acid by aldehyde oxidase of the liver [29]. In the case of phenylacetic acid, its 
excretion was only significatively higher after CC-M than after CC-W in the 
last time period (12-24 h) although the same trend was observed in earlier 
urine fractions.  
  
1.2. Metabolomic study to assess bioavailability and identify nutritional 
biomarkers of exposure after cocoa intake in humans 
 
 Metabolomics aims to assess metabolic changes in a global manner in 
order to provide the detailed biochemical responses of cellular systems and 
provide a comprehensive profile of all the metabolites present in a 
biological sample (metabolome). This approach has been applied to clinical, 
pharmaceutical and toxicological applications [30] and recently has also 
emerged as a field of increasing interest to Food and Nutrition Science                
[31, 32]. We have applied an HPLC-Q-TOF metabolomics approach 
followed by multivariate data analysis (PCA, OSC-PLS and OSC-PLSDA) 
to urine samples collected after a single intake of 40 g of cocoa powder with 
milk (250 mL) or with water (250 mL) or only milk (250 mL) as control, by 
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healthy subjects (n=10; 5 women and 5 men) in a randomized, crossover and 
controlled clinical trial [19]. Our aim in this metabolomic approach was to 
study the influence of cocoa intake on the urinary metabolic profile during 
the time course of a 24 h-urine excretion period (0-6, 6-12, 12-24 h) and to 
identify the most relevant biomarkers of intake. 
 The results revealed that modifications in the urine metabolome as a 
consequence of cocoa intake were explained by the excretion of a complex 
profile of cocoa-derived phytochemicals. A total of 27 metabolites related to 
cocoa intake were identified and were grouped as follows: a) purine alkaloid 
metabolites; b) polyphenol host metabolites; c) polyphenol colonic microbiota 
metabolites, d) cocoa flavour and taste compounds, and e) vitamins and amino 
acids. 
 Among purine alkaloid metabolites, the most important metabolites derived 
from theobromine metabolism, including 6-amino-5-[N-methylformylamino]-1-
methyluracil (AMMU), 3- and 7-methyluric acid, 3- and 7-methylxanthine, 
among others, were identified and were found to be the main contributors to 
changes in the urine metabolome up to 24 h after cocoa intake. In the case of 
polyphenol host metabolites, epicatechin sulfate, O-methylepicatechin, vanillic 
acid, and its derivative vanilloglycine, identified for the first time after cocoa 
intake, were found to be present 6 h  after cocoa powder consumption (Fig. 1) 
[25]. On the other hand, microbial-derived phenolic metabolites, such as 
phenylvaleric acid and phenylvalerolactone derivatives, were found to 
contribute to the urinary metabolome in the period between 6 and 12 h after 
cocoa ingestion (Fig. 1). Cocoa flavoured metabolites identified included             
3,5-diethyl-2-methylpyrazine and hydroxyacetophenone, as well as the 
diketopiperazine derivatives. Finally, trigonellin and hydroxynicotinic acid were 
identified as metabolites derived from nicotinic acid (niacin) present in cocoa, 
whereas tyrosine was identified as a metabolite related to cocoa amino acids. 
Both types of metabolites were found to contribute to changes in urine 
metabolome in the fraction collected 6 h after cocoa intake. 
 These results demonstrate that metabolomics is an important tool for 
exploring the metabolism of cocoa phytochemicals. Metabolites from 
different origins and chemical structures could serve as biomarkers of cocoa 
powder intake and help us to understand if their presence could be related to 
afford health effects. 
 
2. Regular cocoa powder intake: Long-term study  
 
2.1. Effects of cocoa powder on inflammatory biomarkers of atherosclerosis  
  
 The long-term study with regular consumption of cocoa powder was a 
randomized, crossover and controlled clinical trial. The subjects included 
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were diabetic or had three or more of the following cardiovascular disease risk 
factors: tobacco smokers, hypertensives, hypercholesterolemics, and/or obese. 
Forty-two high-risk subjects were included in the study (19 men and 23 
women, mean age of 69.7 years). The institutional review board of the 
hospital approved the study protocol and the trial was registered in the 
International Standard Randomized Controlled Trial Number, at 
controlled.trials.com (ISRCTN75176807). Subjects received two 20 g-sachets 
of soluble cocoa powder per day with 250 mL of skimmed milk each (C+M 
intervention) or only 500 mL skimmed milk per day (M intervention) for 4 
weeks in a random order [20]. We have analyzed the expression of adhesion 
molecules [VLA-4 (very late activation antigen-4, CD49-d), LFA-1 
(lymphocyte function-associated antigen-1, CD11a), Mac-1 (CD11b/CD18), 
SLex (Sialil-Lewis X, CD15s), CD36 and CD40] on the surface of peripheral 
blood mononuclear cells (PBMCs) for the first time after cocoa intake as 
inflammatory biomarkers of atherosclerosis. Our results showed significant 
(p< 0.05) lower values in the expression of adhesion molecules such as           
VLA-4 (-7.4%), CD40 (-6.6%) and CD36 (-21.2%) on monocyte surface after 
consumption of cocoa powder with skimmed milk. 
 Other circulating inflammatory biomarkers studied included serum levels 
of P-selectin, E-selectin, VCAM-1, ICAM-1, proinflammatory cytokine IL-6 
and high-sensitivity C-reactive protein (hs-CRP). It was found that P-selectin 
and ICAM-I, which play an important role in leukocyte adhesion cascade, 
were significantly (p< 0.05) decreased by 10.8% and 9.7%, respectively, after 
the intake of cocoa powder with skimmed milk. Other biomarkers like MCP-1 
and VCAM were also found to be at lower levels (although not significant) 
after cocoa consumption.  
 With respect to plasma lipids, the concentration of HDL cholesterol was 
significantly higher after the intervention of cocoa with skimmed milk in 
comparison to the skimmed milk intervention (4.2% increase, P=0.035). No 
significant changes were observed for total plasma cholesterol, triglycerides 
and LDL cholesterol. In addition, no significant changes were registered in 
systolic and diastolic blood pressure, or in heart rate between the two 
interventions [20]. 
 All the above results strongly support a link between cocoa consumption 
and the modulation of inflammatory mediators in human subjects at high risk 
of CVD. These anti-inflammatory effects together with other previously 
reported effects, including antioxidant, anti-platelet and positive vascular 
effects may contribute to the overall benefits of cocoa consumption against 
atherosclerosis and could have significant implications for public health as far 
as cardiovascular disease is concerned. 
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2.2. Targeted study of cocoa polyphenol metabolites to assess bioavailability 
and compliance  
 
 In order to exert the beneficial effects, cocoa polyphenols need to be 
bioavailable. Monomeric flavanols are readily absorbed in the small intestine 
but polymers need to be degraded by the intestinal microbiota before 
absorption in the colon. We have carried out a targeted study of main cocoa 
polyphenol metabolites by HPLC-MS/MS in the plasma and urine samples 
collected from the clinical study in order to estimate their absorption in vivo 
and as a measure of protocol compliance [21]. Regular consumption of cocoa 
powder with skimmed milk resulted in a significant (p < 0.05) increase in the 
urinary excretion of phase II metabolites, including glucuronide and sulfate 
conjugates of (−)-epicatechin and O-methyl-epicatechin, derived from the 
absorption of epicatechin in the small intestine (Fig. 1). Colonic microbial-
derived phenolic metabolites, including vanillic, 3,4-dihydroxyphenylacetic 
and 3-hydroxyphenylacetic acids, and particularly 5-(3,4-dihydroxyphenyl)-γ-
valerolactone (Fig. 1), were also found in significant higher levels after 
consumption of cocoa powder with skimmed milk and represented the largest 
proportion of total phenolic metabolites excreted in urine. These results 
indicated that cocoa polyphenols are bioavailable and that the colon is an 
active site for the metabolism of cocoa polyphenols. In vitro studies 
performed by our group have suggested that some microbial-derived phenolic 
metabolites possess anti-inflammatory properties, suggesting that they could 
be partly responsible for the benefits observed in patients at high risk of CVD 
after cocoa consumption [33]. 
 
3. Conclusion 
 
 The results presented herein provide valuable information that supports the 
health benefits of cocoa consumption on CVD. New inflammatory biomarkers, 
such as the expression of adhesion molecules on leukocyte surface, have been 
used for the first time in a clinical cocoa trial focused on this issue. Although 
current state of the art does not allow an estimation of CVD risk associated with a 
given change in these or other inflammatory biomarkers, the positive effects 
observed after cocoa consumption may contribute together – along with other 
previously reported effects, in particular on vascular function – to the overall 
benefits of cocoa consumption against CVD. 
 Due to their high content in procyanidins, the colonic microbiota plays a key 
role in the metabolism of cocoa polyphenols, as demonstrated by the increase in 
certain lactones and phenolic acids after cocoa consumption in our targeted study. 
Mireia Urpi-Sarda et al.  130 
Given that these metabolites could represent the largest proportion of all phenolic 
metabolites excreted in urine, more effort needs to be concentrated on the study of 
the biological properties of these microbial-derived phenolic metabolites, 
including their effects on the intestinal microbiota, which are still largely 
unknown.  
 Finally, our metabolomic approach, combined with visualization strategies, 
allowed the identification of a series of metabolites derived from cocoa 
polyphenols, alkaloids, flavour and aroma compounds, vitamins and amino acids 
that could  serve as biomarkers of cocoa powder consumption, thus pushing 
nutritional information one step closer towards a better understanding of  human 
health. 
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